0,95 $
0,94 % vorgestern
Nasdaq, 3. Oktober, 22:00 Uhr
ISIN
US00444T1007
Symbol
TLPH
Berichte

AcelRx Pharmaceuticals, Inc. Aktie News

Neutral
GlobeNewsWire
27 Tage alt
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-marke...
Neutral
PRNewsWire
27 Tage alt
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The com...
Neutral
PRNewsWire
etwa ein Monat alt
The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif. , Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercializa...
Neutral
Seeking Alpha
etwa 2 Monate alt
Talphera, Inc. (NASDAQ:TLPH ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Raffi Mark Asadorian - Chief Financial Officer Shakil Aslam - Chief Medical Officer Vincent J. Angotti - CEO & Director Conference Call Participants Antonio Eduardo Arce - WestPark Capital, Inc. James Francis Molloy - Alliance Global Partners, Research Division Nazibur Rahman - Maxim G...
Neutral
PRNewsWire
etwa 2 Monate alt
New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif. , Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH)...
Neutral
PRNewsWire
etwa 2 Monate alt
SAN MATEO, Calif. , Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and ...
Neutral
Seeking Alpha
5 Monate alt
Talphera, Inc. (NASDAQ:TLPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Shakil Aslam - Chief Medical Officer Conference Call Participants Operator Welcome to the Talphera First Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page ...
Neutral
PRNewsWire
5 Monate alt
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen